Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026195 · ClinicalTrials.gov registry record · Phase 1
Irinotecan in Treating Aging Patients With Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT00026195: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Alliance for Clinical Trials in Oncology.
NCT00026195 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 140 participants, below the 499-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026195, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Aging may affect the way these drugs work. PURPOSE: Phase I trial to determine the relationship between aging and the effectiveness of irinotecan in treating patients who have solid tumors.
Conditions Studied
Interventions
- DRUG irinotecan hydrochloride
Study Locations (20)
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- Veterans Affairs Medical Center - San Francisco - San Francisco
- UCSF Comprehensive Cancer Center - San Francisco
Illinois
- MBCCOP - University of Illinois at Chicago - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
District of Columbia
- Lombardi Cancer Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Massachusetts
- Dana-Farber Cancer Institute - Boston
- University of Massachusetts Memorial Medical Center - University Campus - Worcester
Minnesota
- Veterans Affairs Medical Center - Minneapolis - Minneapolis
- University of Minnesota Cancer Center - Minneapolis
Missouri
- Veterans Affairs Medical Center - Columbia (Truman Memorial) - Columbia
- Ellis Fischel Cancer Center - Columbia - Columbia
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Florida
- CCOP - Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2001-09 |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
What the finished NCT00026195 record still lists
NCT00026195 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 499-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which irinotecan hydrochloride is the first listed.
NCT00026195 names 20 study sites across 11 states, led by California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00026195 about?
NCT00026195 is a clinical study titled "Irinotecan in Treating Aging Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Aging may affect the way these drugs work. PURPOSE: Phase I trial to determine the relationship between aging and the effectiveness of irinotecan in treating patients who have sol...
What is the current status of trial NCT00026195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2001-09. Estimated completion is 2006-06.
What conditions does trial NCT00026195 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00026195?
The interventions under investigation include: irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00026195?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026195 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00026195's enrollment target sits among peer trials
140 15th of 83 higher than 68 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia